Navigation Links
Genes as Time Machines
Date:2/6/2008

3.5 Billion Year-Old Genes Resurrected to Serve as Probes of Early Life on

Earth.

GAINESVILLE, Fla., and MENLO PARK, Calif., Feb. 6 /PRNewswire/ -- Scientists at the Foundation for Applied Molecular Evolution, University of Florida (both at Gainesville, FL) and DNA2.0 (Menlo Park, CA) today publish a study in the journal Nature where more than 20 ancient genes were resurrected from organisms that lived between 500 million to 3.5 billion years ago.

"By studying proteins encoded by these primordial genes, we are able to infer information about the environmental conditions of the early Earth" said Dr. Eric Gaucher at the Foundation for Applied Molecular Evolution and lead scientist of the study. "Genes evolve to adapt to the environmental conditions in which an organism lives. Resurrecting these long extinct genes gives us the opportunity to analyze and dissect the ancient surroundings that have been recorded in the gene sequence. The genes essentially behave as dynamic fossils."

The researchers chose a gene that encodes a protein which captures the environmental temperature of the gene's host organism. In essence, the resurrected genes are ancient thermometers. These 'thermometers' were used to provide evidence that the oldest bacterial life forms lived at a hot temperature of 75 degrees C (~165 degrees F) 3.5 billion years ago, and slowly cooled to a temperature of 40 degrees C (~100 degrees F) by 500 million years ago.

"Remarkably, our results are nearly identical to geologic studies that estimate the temperature trend for the ancient ocean over the same time period. The convergence of results from biology and geology show that Earth's environment has continuously been changing since life began, and life has adapted appropriately to survive," said Dr. Gaucher.

"Although the concept of ancestral gene resurrection was proposed more than forty years ago, the development of efficient gene synthesis has only recently enabled the creation of the ancestral genes required for a study like this" said Dr. Sridhar Govindarajan, co-author of the paper and scientist at DNA2.0, the gene synthesis company that built the ancestral genes. "Gene synthesis allows for a direct route from a calculated gene sequence to a protein that can be tested for function in the laboratory."

Dr. Omjoy Ganesh, a structural biologist at the University of Florida, also contributed to this research.

About the Foundation for Applied Molecular Evolution

FfAME is a non-profit research organization combining computational, chemical, molecular and life sciences to uniquely create a vertically integrated approach that generates opportunities to transfer technology from basic research to meet demands in commerce and medicine. For more information, visit http://www.ffame.org

About DNA2.0

DNA2.0 is the largest US provider of synthetic genes, serving customers globally in the pharmaceutical and biotechnology industries as well as in academia. The company is also applying machine learning to protein engineering through their ProteinGPS(TM) platform. For more information, visit http://www.DNA20.com


'/>"/>
SOURCE Foundation for Applied Molecular Evolution; DNA2.0, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
2. Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference
3. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
4. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
5. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
6. Cell Genesys to Present at the BIO Investor Forum
7. Stallergenes : 3rd Quarter Sales Up 17%: 9- Month Cumulative Sales Up 17%
8. Massive reanalysis of genome data solves case of the lethal genes
9. Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th
10. Cell Genesys to Webcast Third Quarter 2007 Conference Call
11. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... -- According to the new market ... Instruments, Automated Cell Expansion System), Cells Types (Human, ... Cancer, and Cell-Based Research), End-users (Biopharmaceutical and Biotechnology ... Trends, Growth, Share, Size and Forecast to 2022", ... expansion market is expected to reach USD 18.74 ...
(Date:12/5/2016)... Mich. , Dec. 5, 2016 NxGen MDx announced today ... bringing the test in house, we,ve been able to improve customer service ... for patients," says Alan Mack , CEO of NxGen MDx. ... , , ... test volume has led to more job opportunities at the Grand Rapid ...
(Date:12/5/2016)... -- The U.S. Biotechnology industry is the ... revenue and some $890 billion of total market value. In ... and this figure is expected to exceed $220 billion ... four equities for assessment: Northwest Biotherapeutics Inc. (NASDAQ: ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ACOR ...
(Date:12/4/2016)...  In five studies being presented today during the ... Exposition in San Diego , researchers ... delivery of life-saving treatments to patients with a variety ... carry therapies directly to the sites in the body ... substantial advantage over traditional, systemic methods. The studies highlight ...
Breaking Biology Technology:
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):